The expression of ghrelin in somatotroph and other types of pituitary adenomas

Neuroendocrinology Letters

Volumn 29, Issue 6, 2008, Pages 929-938

  Wasko, Ryszard ^a   Jaskula, Magdalena ^a   Kotwicka, Malgorzata ^a   Andrusiewicz, Miroslaw ^a   Jankowska, Anna ^a   Liebert, Wlodzimierz ^a   Sowinski, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Ghrelin; Immunohistochemistry; Non functioning pituitary adenomas; Octreotide LAR; Pituitary adenomas; Prolactinomas; Reverse transcription polimerase chain reaction; Somatotroph adenomas

Indexed keywords

GHRELIN; MESSENGER RNA; OCTREOTIDE;

ACTH SECRETING ADENOMA; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; NEUROSURGERY; NONFUNCTIONING PITUITARY ADENOMA; NUCLEOTIDE SEQUENCE; PREOPERATIVE CARE; PROLACTINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 59949093754     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature; 402: 656-660.
2. Van der Lely A, Tschop M, Heiman ML, Ghigo E. et al. (2004).. Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin. Endor Rev; 25(3): 426-457.
3. Kojima M, Kangawa K. et al. (2005). Ghrelin: structure and function. Physiol Rev; 85: 495-522.
4. Kojima M, Hosoda H, Matsuo H, Kangawa K. et al. (2001). Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends in Endocrinol Metab; 12: 118-122.
5. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshomoto A, Harada M et al. (2000) Ghrelin strongly stimulates growth hormone (GH) release in humans. J Clin Endocr Metab 85, 4908-4911.
6. Yoshihara F, Kojima M, Hosoda H, Nakazato M, Kangawa K. et.al. (2002). Ghrelin: a novel peptide for growth hormone release and feeding regulation. Curr Opin Clin Nutr Metab Care; 5: 391-395.
7. Peino R, Baldelli R, Rodriguez-Garcia J et al. (2000). Ghrelin-induced growth hormone secretion in humans. Eur J Endorinol; 143: R11-14.
8. Hataya Y, Akamizu T, Takaya K, Kanamoto N, Ariyasu H, Saijo M et al. (2001). A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH - releasing hormone in humans. J Clin Endocr Metab 86: 4552-4556.
9. Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, et al. (2002). Ghrelin man action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab; 88(7): 3450-3453.
10. Horvath TL, Diano S, Sotonyi P, Heiman ML, Tschop M. (2002) Ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology; 142, 4163.
11. Ghigo E, Broglio F, Arvat E, Maccario M, Papotti M, Muccioli G. (2005) Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol; 62: 1-17.
12. Leite-Moreira AF, Soares J-B. (2007). Physiological, pathological and potential therapeutic role of ghrelin. Drug Discovery Today; 12(7/8): 276-288.
13. Kojima M, Hosoda H, Kangawa K. (2001). Purification and distribution of ghrelin: the natural endogenous ligand of growth hormone secretagogue receptor. Horm Research, 56: 93-97.
14. Date Y, Kojima M, Hosoda H et al. (2000). Ghrelin, a novel growth hormone acyclated peptide, is synthesized in the gastrointestinal tract of rats and humans. Endocrinol., 141, 4255.
15. Gnanapavan S, Kola B, Bustin S.A., Morris DG, McGee P, Fairclough P et al. (2002). The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab; 87, 2988-2994.
16. Kagotani Y, Sakata I, Yamazaki M, Nakamura K, Hayashi Y, Kagawa K. (2001). Localization of ghrelin - immunopositive cells in the rat hypothalamus and intestinal tract. Proceedings of the 83rd AnnualMeeting of the Endocrine Society, Denver,CO, 337.
17. Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R. (2001) Binding of 1251-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 2001; 24: RC7-RC9.
18. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG et al. (2001) The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumours. J Clin Endocrinol Metab; 86: 881-887.
19. Korbonits M, Kojima M, Kangawa K, Grossman AB (2001) Presence of ghrelin in normal and adenomatous human pituitary. Endocrine; 14: 101-105.
20. Caminos JE, Nogueiras R, Blanco M, Seoane LM, Bravo S, Alvarez CV, et al. (2003) Cellular Distribution and Regulation of Ghrelin Messenger Ribonucleic Acid in the Rat Pituitary Gland. Endocrinol; 144(11): 5089-5097.
21. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Oikawa S. Regulation of the ghrelin gene: growth hormone-releasing hormone upregulates ghrelin mRNA in the pituitary.
22. Maccarinelli G. et al. (2005). Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol; 184: 249-256.
23. Pettersson I, Muccioli G, Granata R, Deghenghi R, Ghigo E, Ohlsson C, et. al. (2002). Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol; 175: 201-9.
24. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al. (2002). Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 30kinase/AKT. J Cell Biol; 159: 1029-1037.
25. Delhanty PJ, van Koetsveld PM, Gauna C, van de Zande B, Vitale G, Hofland LJ, et al. (2007). Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumorr cells via an anti-apoptotic pathway. Am J Physiol Endocrinol Metab; 293(1): E302-9.
26. Ghe C, Cassoni P, Catapano F, Marrocco T, Deghenghi R, Ghigo E, et al. (2002). The Antiproliferative Effect of Synthetic Peptidyl GH Secretagogues in Human CALU-1 Lung Carcinoma Cells. Endocrinol; 143(2): 484-491.
27. Nanzer A, Khalaf S, Mozid A, Fowkes R, Patel M, Burrin J, et.al. (2004). Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol 2004; 151 233-240.
28. Volante M. Allia, E., Fulcheri, E., Cassoni, P., Ghigo, E., Muccioli, G. et al. (2003). Ghrelin in fetal thyroid and follicular tumours and cell lines: expression and effects on tumour growth. Am J Pathol; 162: 645-654.
29. Andreis PG, Malendowicz LK, Trejter M, Neri G, Spinazzi R, Rossi GP et al. (2003) Ghrelin and growth hormone secretagogue receptor are expressed in the rat adrenal cortex: evidence that ghrelin stimulates the growth, but not the secretory activity of adrenal cells. FEBS Letters; 536 173-179.
30. Cassoni P, Papotti M, Catapano F, Ghe C, Deghenghi R, Ghigo E. et al. (2000). Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. J Endocrinol; 165: 139-146.
31. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A, et. al. (2001). Identification, characterization and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues in human breast carcinomas and cell lines. J Clin Endocrinol Metab 86: 1738-1745.
32. Delhanty PJ, van Koetsveld PM, Gauna C, van de Zande B, Vitale G, Hofland LJ, et al. (2007). Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumorr cells via an anti-apoptotic pathway. Am J Physiol Endocrinol Metab; 293(1): E302-9.
33. Kim K, Arai K, Sanno N, Osamura RY, Teramoto A, Shibasaki T. (2001). Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas. Clin. Endocrinol. 54, 759.
34. Korbonits M, Jacobs R, Aylwin S, Burin J, Dahia P, Monson J et.al. (1998). Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. J Clin Endocrinol Metab; 83(10): 3624-3630.
35. Papotti M, Ghe C, Cassoni P, Catapano F, Deghengi R, Ghigo E et. Al. (2000). Growth hormone secretagogue binding sites in peripherial human tissues. J.Clin.Endocrinol.Metab; 85,3803
36. Casanueva FF, Dieguez C. (2005). Leptin and ghrelin: what is the impact on pituitary function? Rev Endocr Metab Disord; 6:39-45.
37. Jeffery PL, Herington AC, Chopin LK. (2003). The potential autocrine/ paracrine roles of ghrelin and its receptor in hormone-dependent cancer. Cytokine Growth Factor Rev; 14: 113-122.
38. Thapar K, Kovacs K, Stefaneanu L, Scheithauer B, Killinger DW, Lioyd RV. (1997). Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors An event associated with neoplastic progression and aggressive behavior. Am J Pathol 151:769-784
39. Krsmanovic LZ, Martinez-Fuentes AJ, Arora KK, Mores N, Tomic M, Stojilkovic SS. (2000). Local regulation of gonadotroph function by pituitary gonadotropin-releasing hormone. Endocrinology 141:1187-1195.
40. Levy L, Bourdais J, Mouhieddine B, Benlot C, Villares S, Cohen P. (1993). Presence and characterization of the somatostatin precursor in normal human pituitaries and in growth hormone secreting adenomas. J Clin Endocrinol Metab 76:85-90.
41. Asa SL, Ezzat S. (1998). The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev; 19(6): 798-827.
42. Peillon F, Le Dafniet M, Garnier P, Feinstein MC, Donnadieu M, Barret A, et. al. (1989). Brandi AM, Benlot C, Lagoguey A, Lefebvre P, Blumberg-Tick J, Joubert D. Neurohormones coming from the normal and tumoral human anterior pituitary. Secretion and regulation in vitro. Pathol Biol; 37: 840-845.
43. Joubert (Bression) D, Benlot C, Lagoguey A, Garnier P, Brandi AM, Gautron JP, et. al. (1989). Normal and growth hormone (GH)-secreting adenomatous human pituitaries release somatostatin and GH-releasing hormone. J Clin Endocrinol Metab; 68: 572-577
44. Levy A, Lightman SL. (1992). Growth hormone-releasing hormone transcripts in human pituitary adenomas. J Clin Endocrinol Metab; 74: 1474-1476.
45. Matsuno A, Katakami H, Sanno N, Ogino Y, Osamura RY, Matsukura S. (1999). Pituitary somatotroph adenoma producing growth hormone (GH) releasing hormone (GHH) with an elevated plasma GHRH concentration: a model case for autocrine and paracrine regulation of GH secretion by GHRH. J Clin Endocrinol Metab; 84: 3241-3247.
46. Levy L, Bourdais J, Mouhieddine B, Benlot C, Vilares S, Cohen P, et. al. (1993). Presence and characterisation of the somatostatin precursor in normal human pituitaries and in growth hormone secreting adenomas. J Clin Endocrinol Metab; 76: 85-90.
47. Asa SL, Scheithauer BW, Bilbao JM, Horvath E, Ryan N, Kovacs K, et al. (1984). A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab; 58:796-803.
48. Skinner MM, Nass R, Lopes B, Laws ER, Thorner MO. (1998). Growth hormone secretagogue receptor expression in humar pituitary tumors. J Clin Endocrinol Metab.; 83, 4314.
49. Volante M, Allia E, Gugliotta P, Funaro A, Broglio F, Deghenghi R, et.al. (2002). Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 87: 1300-1308.
50. Kanamoto, N., Akamizu, T., Hosoda, H., Hataya, Y., Ariyasu H., Takaya K. et.al. (2001) Substantial production of ghrelin by a human medullary thyroid carcinoma cell line. Journal of Clinical Endocrinology and Metabolism, 86, 4984-4990.
51. Iwakura, H., Hosoda, K., Doi, R., Komoto, I., Nishimura, H., Son, C. et al. (2002) Ghrelin expression in islet cell tumors: augmented expression of ghrelin in a case of glucagonoma with multiple endocrine neoplasm type I. Journal of Clinical Endocrinology and Metabolism, 87, 4885-4888.
52. Jeffery, P.L., Herington, A.C. & Chopin, L.K. (2002) Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. Journal of Endocrinology. 172, R7-R11.
53. Hubina E, Ruscica M, Nanzer AM, Czirják S, Góth MI, Grossman AB, et al. (2005). Novel molecular aspects of pituitary adenomas. J Endocrinol Invest.; 28(11) Suppl International:87-92.
54. Kovacs K, Horvath E. (1987). Pathology of pituitary tumors. Endocrinol Metab Clin North Am.; 16:529-551.
55. Shimon I, Melmed S. (1997). Pituitary tumor pathogenesis. 82(6): 1675-1681.
56. Spada A. (1998) Growth factors and human pituitary adenomas. Eur J Endocrinol; 138: 255-257.
57. Billestrup N, Swanson LW, Vale W. (1986). Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA; 83: 6854-6857
58. Granata R, Settani F, Biancone L, Trovato L, Nano R, Bertuzzi F. et al. (2007). Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3′, 5′ - cyclic adenosine monophosphate/protein kinase A, extracellulae signal-regulated kinase 1/2 and phosphatidyl inositol 3-Kinase/Akt signaling. Endocrinology; 148(2): 512-529.
59. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, et al. (2005) Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone; 37(3):359-69.
60. Li A, Cheng G, Zhu GH, Tarnawski AS. (2007). Ghrelin stimulates angiogenesis in human microvascular endothelial cells: implications beyond GH release. Biochem Biophys Res Commun.; 353(2): 238-243.
61. Pollak MN, Schally AV. (1998). Mechanisms of neoplastic action of somatostatin analogs. Proc Soc Exp Biol Med; 217: 143-152.
62. Danila DC, Sleiman Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab; 86(7): 2976-2981.
63. Bevan J. (2004). The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab; 89: 1093.
64. Lamberts SWJ. (1998). The role of somatostatin in the regulation of anterior pituitary hormones and the use of its analogues in the treatment of human pituitary tumors. Endocrine Rev; 9: 417-436.
65. Krantic S., Goddart I., Savean A. et al. (2004). Novel modalities of somatostatin actions. Eur J Endocrinol; 151: 643-655.
66. Vitale G, Pivonello R, Ferone D, De Martino MC, Auriemma RS, Caraglia M. (2004) The role of somatostatin receptors in the medical treatment of acromegaly. Dig Liver Dis. Feb;36 Suppl 1:S55-9.
67. Florio T., Thellung S., Arena S. et al. (1999). Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol; 144: 396-408.
68. 3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinol, 136: 4174-81.
69. Pawlikowski M, Mełen-Mucha G. (2003). Perspectives of new potential therapeutic applications of somatostatin analogs. Neuroendocrinol Lett; 24: 21-27.
70. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, (1997). Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs; 15, 77-86.
71. Imam H, Erikson B, Lukinius A et al. (1997). Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol; 36: 607-614.
72. Castano JP, Delgado-Niebla E, Duran-Prado M, Luque RM, Sanchez-Hormigo A, Gracia-Navarro F. et al. (2005). New insights in the mechanism by which SRIF influences GH secretion. J Endocrinol Invest; 28(5 Suppl): 10-13.
73. Hubina E, Nanzer AM, Hanson M, Ciccarelli E, Losa M, Gaia D, et al. (2006). Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol; 155: 371-379.
74. Garcia A, Alvarez CV, Smith RG, Dieguez C. (2001). Regulation of PIT-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Fndocrinol; 15(9): 1484-1495.
75. Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP. (1993). Cell Type-Specific Expression of the Pituitary Transcription Activator Pit-I in the Human Pituitary and Pituitary Adenomas. J Clin Endocrinol Metab; 77(5): 1275-1280.
76. Friend KE, Chiou Y-K, Laws ER, Lopes MB, Shupnik MA. (1993). Pit-1 Messenger Ribonucleic Acid Is Differentially Expressed in Human Pituitary Adenomas. J Clin Endocrinol Metab; 17(5): 1281-1286.